REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot99210.21518/1561-5936-2020-9-46-50Original ArticleBronchial asthma: fundamental changes in the new GINA guidelines(2019)VodovozovAlekseynoemail@neicon.ruRemedium091220209465018032022Copyright © 2020,2020The new guidelines of the Global Initiative for Asthma (GINA) has inspired a heated discussion among experts. The next version was published in 2018, but its revision appeared as early as in 2019. This is primarily due to the revision of the attitude towards short-acting beta-2-agonists, however, the approaches have changed significantly at other stages of bronchial asthma treatment as well, especially at the early stages. The emphasis has been placed on low-dose inhaled corticosteroids, as they have accumulated an evidence base at an adequate quality level. In fact, the 2019 GINA proposals are reduced to discontinuation of the common clinical practice and switching to fundamentally different approaches to the management of bronchial asthma, especially its mild form.bronchial asthmainhaled corticosteroidsbeta-2 agonistsclinical guidelinesGINAбронхиальная астмаингаляционные кортикостероидыбета-2-агонистыклиническое руководство1.Визель А.А. Бронхиальная астма: современные тенденции в лечении. Вестник современной клинической медицины. 2011;4(3):14-17.2.Soriano J.B., Abajobir A.A., Abate K.H., Abera S.F., Agrawal A., Ahmed M.B. et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet Respir Med. 2017;5(9):691-706.3.Ebmeier S., Thayabaran D., Braithwaite I., Bénamara C., Weatherall M., Beasley R. Trends in international asthma mortality: analysis of data from the WHO mortality database from 46 countries (1993-2012). Lancet. 2017;390(10098):935-945.4.Dusser D., Montani D., Chanez P., de Blic J., Delacourt C., Deschildre A. et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591-604.5.Levy M.L., Andrews R., Buckingham R., Evans H., Francis C., Houston R. et al. Why asthma still kills: the National Review of asthma deaths (NRAD) confidential enquiry report. London, UK: Royal College of Physicians; 2014.6.Papi A., Brightling C., Pedersen S.E., Reddel H.K. Asthma. Lancet. 2018;391(10122):783-800.7.Global Initiative for Asthma. Global strategy for asthma management and prevention. 2019. Available at: https://ginasthma. org/pocket-guide-for-asthma-management-and-prevention/ (дата обращения: 24.02.2020).8.Bateman E.D., Reddel H.K., O’Byrne P.M., Barnes P.J., Zhong N., Keen C. et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877-1887.9.Barnes C.B., Ulrik C.S. Asthma and adherence to inhaled cor- ticosteroids: current status and future perspectives. Respir Care. 2015;60(3):455-468.10.Beasley R., Weatherall M., Shirtcliffe P., Hancox R., Reddel H.K. Combination corticosteroid/beta-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma? J Allergy Clin Immunol. 2014;133(1):39-41.11.Suissa S., Ernst P., Boivin J.F., Horwitz R.I., Habbick B., Cockroft D. et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994;149(3):604-610.12.Stanford R.H., Shah M.B., D’Souza A.O., Dhamane A.D., Schatz M. Short-acting β-agonist use and its ability to predict future asthma- related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403- 407.13.O’Byrne P.M., FitzGerald J.M., Bateman E.D., Barnes P.J., Zhong N., Keen C. et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865-1876.14.Papi A., Canonica G.W., Maestrelli P., Paggiaro P., Olivieri D., Pozzi E. et al. Rescue use of beclomethasone and albuterol in a sin- gle inhaler for mild asthma. N Engl J Med. 2007;356(20):2040-2052.15.Calhoun W.J., Ameredes B.T., King T.S., Icitovic N., Bleecker E.R., Castro M. et al. Comparison of physician-, biomarker-, and symp- tom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA. 2012;308(10):987-997.16.Martinez F.D., Chinchilli V.M., Morgan W.J., Boehmer S.J., Lemanske R.F. Jr., Mauger D.T. et al. Use of beclomethasone dipro- pionate as rescue treatment for children with mild persistent asth- ma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9766):650-657.17.Martin M.J., Harrison T.W. Is it time to move away from short-acting beta-agonists in asthma management? Eur Respir J. 2019;53(4).18.Aldridge R.E., Hancox R.J., Robin Taylor D., Cowan J.O., Winn M.C., Frampton C.M. et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med. 2000;161(5):1459-1464.19.Sears M.R., Taylor D.R., Print C.G., Lake D.C., Li Q., Flannery E.M. et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990;336(8728):1391-1396.20.Reddel H.K., Busse W.W., Pedersen S., Tan W.C., Chen Y.Z., Jorup C. et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017;389(10065):157-166.21.Beasley R., Holliday M., Reddel H.K., Braithwaite I., Ebmeier S., Hancox R.J. et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380:2020-2030.22.Lazarus S.C., Krishnan J.A., King T.S., Lang J.E., Blake K.V., Covar R. et al. Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. N Engl J Med. 2019;380(21):2009-2019.23.Wong G.W.K. How should we treat patients with mild asthma? N Engl J Med. 2019;380(21):2064-2066.